Needham & Company Cuts Target on Vivus (VVUS), Adjusts Qsymia Estimates
Tweet Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $15.04 +3.72%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Trade VVUS Now!
Needham & Company cut its price target on Vivus (NASDAQ: VVUS) from $38 to $32 following a disclosure last Friday that a negative CHMP decision for Qsymia is likely when announced next month. The firm is also updated sales estimates with the commercial launch of Qsymia.
"Based on our discussions with management, the European regulatory environment appears less accommodating to new weight loss drugs than we had appreciated," analyst Alan Carr states. "We do not expect Qsymia approval in that region in the near future and have removed E.U. sales and collaboration revenue from our models."
Needham is lowering 2012 and 2013 U.S. Qsymia sales estimates to $10.6M (was $25M) and $258.9M (was $290M), to reflect accounting guidance (20% G-N; No stocking at launch). They are revising 2014 and 2015 sales estimates upwards to $469M (was $410M) and $618M (was $490M) based on a historical analysis of other obesity and metabolic drugs.
"Last, we remind investors that we believe litigation with J&J is a meaningful possibility subsequent to first sale of Qsymia," Carr states. "We conservatively assume a royalty payment to J&J of up to 10%, which is embedded in our COGS estimate."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $21.00 yesterday, with a 52 week range of $7.47-$31.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"Based on our discussions with management, the European regulatory environment appears less accommodating to new weight loss drugs than we had appreciated," analyst Alan Carr states. "We do not expect Qsymia approval in that region in the near future and have removed E.U. sales and collaboration revenue from our models."
Needham is lowering 2012 and 2013 U.S. Qsymia sales estimates to $10.6M (was $25M) and $258.9M (was $290M), to reflect accounting guidance (20% G-N; No stocking at launch). They are revising 2014 and 2015 sales estimates upwards to $469M (was $410M) and $618M (was $490M) based on a historical analysis of other obesity and metabolic drugs.
"Last, we remind investors that we believe litigation with J&J is a meaningful possibility subsequent to first sale of Qsymia," Carr states. "We conservatively assume a royalty payment to J&J of up to 10%, which is embedded in our COGS estimate."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $21.00 yesterday, with a 52 week range of $7.47-$31.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
- Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
